Letter to House re Immunocompromised Patients and COVID Funding

American Society of Hematology. (2022).
Letter to House re Immunocompromised Patients and COVID Funding.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/letter-to-house-re-immunocompromised-patients-and-covid-funding.

American Society of Hematology.
"Letter to House re Immunocompromised Patients and COVID Funding." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/letter-to-house-re-immunocompromised-patients-and-covid-funding
(label-accessed April 26, 2024).

"American Society of Hematology."
Letter to House re Immunocompromised Patients and COVID Funding, 26 Apr. 2024 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/letter-to-house-re-immunocompromised-patients-and-covid-funding.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero